Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Artios Pharma Limited has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners, indicating that the workload is split evenly between different reviewers. This distribution allows for a broader range of examiner perspectives within the company's active portfolio, as no single individual is responsible for both pending cases. For the practitioner, this means that the prosecution strategy must be adapted to the specific tendencies of two different examiners.
Both pending actions are located within 1 distinct art unit. NOLAN, JASON MICHAEL is the busiest examiner with 1 pending office action. This structure shows that while the technical area is unified within a single art unit, the company is interacting with multiple examiners to advance its 2 pending cases. This can be advantageous for the applicant, as it provides multiple opportunities to secure favorable outcomes within the same technical group, even if one examiner proves more difficult than the other. The concentration in one art unit suggests a consistent technical standard will be applied across both matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOLAN, JASON MICHAEL | 1 | 66.6% | -27.2% |
| KUCHARCZK, JED A | 1 | 80.4% | +16.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18699286 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | KUCHARCZK, JED A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18699286 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | KUCHARCZK, JED A | — |
| Art Unit | Apps |
|---|---|
| 1623 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18701664 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NOLAN, JASON MICHAEL | 1623 | §112 | Non-Final OA | — | Pending | Apr 16, 2024 |
| 18699286 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | KUCHARCZK, JED A | 1623 | §101§112DP | Non-Final OA | — | Pending | Apr 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialArtios Pharma Limited has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Jason Michael Nolan has the most, with 1 of Artios Pharma Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
